SAMSUNG-ELECTRONICS
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced two new ISOCELL Vizion sensors — a time-of-flight (ToF) sensor, the ISOCELL Vizion 63D, and a global shutter sensor, the ISOCELL Vizion 931. First introduced in 2020, Samsung’s ISOCELL Vizion lineup includes ToF and global shutter sensors specifically designed to offer visual capabilities across an extensive range of next-generation mobile, commercial and industrial use cases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231219353837/en/
Samsung Unveils Two New ISOCELL Vizion Sensors Tailored for Robotics and XR Applications (Graphic: Business Wire)
“Engineered with state-of-the-art sensor technologies, Samsung’s ISOCELL Vizion 63D and ISOCELL Vizion 931 will be essential in facilitating machine vision for future high-tech applications like robotics and extended reality (XR),” said Haechang Lee, Executive Vice President of the Next Generation Sensor Development Team at Samsung Electronics. “Leveraging our rich history in technological innovation, we are committed to driving the rapidly expanding image sensor market forward.”
ISOCELL Vizion 63D: Tailored for capturing high-resolution 3D images with exceptional detail
Similar to how bats use echolocation to navigate in the dark, ToF sensors measure distance and depth by calculating the time it takes the emitted light to travel to and from an object.
Particularly, Samsung’s ISOCELL Vizion 63D is an indirect ToF (iToF) sensor that measures the phase shift between emitted and reflected light to sense its surroundings in three dimensions. With exceptional accuracy and clarity, the Vizion 63D is ideal for service and industrial robots as well as XR devices and facial authentication where high-resolution and precise depth measuring are crucial.
The ISOCELL Vizion 63D sensor is the industry’s first iToF sensor with an integrated depth-sensing hardware image signal processor (ISP). With this innovative one-chip design, it can precisely capture 3D depth information without the help of another chip, enabling up to a 40% reduction in system power consumption compared to its predecessor. The sensor can also process images at up to 60 frames per second in QVGA resolution (320x240), which is a high-demand display resolution used in commercial and industrial markets.
Based on the industry’s smallest 3.5㎛ pixel size in iToF sensors, the ISOCELL Vizion 63D achieves high Video Graphics Array (VGA) resolution (640x480) within a 1/6.4” optical format, making it an ideal fit for compact, on-the-go devices.
Thanks to backside scattering technology (BST) that enhances light absorption, the Vizion 63D sensor boasts the highest level of quantum efficiency in the industry, reaching 38% at an infrared light wavelength of 940 nanometers (nm). This enables enhanced light sensitivity and reduced noise, resulting in sharper image quality with minimal motion blur.
Moreover, the ISOCELL Vizion 63D supports both flood (high-resolution at short-range) and spot (long-range) lighting modes, significantly extending its measurable distance range from its predecessor’s five meters to 10.
ISOCELL Vizion 931: Optimized for capturing dynamic movements without distortion
The ISOCELL Vizion 931 is a global shutter image sensor tailored for capturing rapid movements without the “jello effect”. Unlike rolling shutter sensors that scan the scene line by line from top to bottom in a “rolling” manner, global shutter sensors capture the entire scene at once or “globally,” similar to how human eyes see. This allows the ISOCELL Vizion 931 to capture sharp, undistorted images of moving objects, making it well-suited for motion-tracking in XR devices, gaming systems, service and logistics robots as well as drones.
Designed in a one-to-one ratio VGA resolution (640 x 640) that packs more pixels in a smaller form factor, the ISOCELL Vizion 931 is optimal for iris recognition, eye tracking as well as facial and gesture detection in head-mounted display devices like XR headsets.
The ISOCELL Vizion 931 also achieves the industry’s highest level of quantum efficiency, delivering an impressive 60% at 850nm infrared light wavelength. This feat was made possible by incorporating Front Deep Trench Isolation (FDTI) which places an insulation layer between pixels to maximize light absorption, in addition to the BST method used in the ISOCELL Vizion 63D.
The Vizion 931 supports multi-drop that can seamlessly connect up to four cameras to the application processor using a single wire. With minimal wiring required, the sensor provides greater design flexibility for device manufactures.
Samsung ISOCELL Vizion 63D and ISOCELL Vizion 931 sensors are currently sampling to OEMs worldwide.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219353837/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom